In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating DocGo DCGO against its key competitors in the Health Care Providers & Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
DocGo Background
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. DocGo is disrupting the traditional four-wall healthcare system by providing care at the scale of humanity. Its technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace.
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
DocGo Inc | 49.14 | 1.24 | 0.67 | 1.68% | $0.01 | $0.06 | 78.83% |
Pediatrix Medical Group Inc | 9 | 0.83 | 0.39 | 2.24% | $0.05 | $0.11 | 3.41% |
Cross Country Healthcare Inc | 8.05 | 1.70 | 0.37 | 2.73% | $0.02 | $0.1 | -30.47% |
Pennant Group Inc | 38.48 | 3.60 | 0.93 | 3.33% | $0.01 | $0.02 | 18.46% |
InfuSystems Holdings Inc | 220.38 | 4.10 | 1.81 | 1.36% | $0.0 | $0.02 | 16.97% |
Prenetics Global Ltd | 1.07 | 0.25 | 0.16 | -6.17% | $-0.01 | $0.0 | 13.27% |
Average | 55.4 | 2.1 | 0.73 | 0.7% | $0.01 | $0.05 | 4.33% |
When analyzing DocGo, the following trends become evident:
-
At 49.14, the stock's Price to Earnings ratio is 0.89x less than the industry average, suggesting favorable growth potential.
-
With a Price to Book ratio of 1.24, significantly falling below the industry average by 0.59x, it suggests undervaluation and the possibility of untapped growth prospects.
-
Based on its sales performance, the stock could be deemed undervalued with a Price to Sales ratio of 0.67, which is 0.92x the industry average.
-
The company has a higher Return on Equity (ROE) of 1.68%, which is 0.98% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
-
Compared to its industry, the company has a similar Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $10 Million, suggesting comparable profitability and operational efficiency.
-
With higher gross profit of $60 Million, which indicates 1.2x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
-
The company is experiencing remarkable revenue growth, with a rate of 78.83%, outperforming the industry average of 4.33%.
Debt To Equity Ratio
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
In terms of the Debt-to-Equity ratio, DocGo can be assessed by comparing it to its top 4 peers, resulting in the following observations:
-
As DocGo is in the middle of the list in terms of the debt-to-equity ratio, it suggests that the company has a moderate debt-to-equity ratio of 0.07 compared to the other companies.
-
This position indicates a relatively balanced financial structure, where the company maintains a reasonable level of debt while also leveraging equity for financing its operations.
Key Takeaways
For the valuation analysis of DocGo in the Health Care Providers & Services industry, the PE, PB, and PS ratios indicate that the company is undervalued compared to its peers. The high ROE suggests that DocGo is generating strong returns on shareholder equity. The EBITDA ratio indicates that the company's earnings are in line with its peers. The high gross profit and revenue growth ratios suggest that DocGo is experiencing strong profitability and growth in comparison to its industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.